Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-GPC3 aptamer
- Development stage
- Preclinical
- Lead developer
- Band Therapeutics
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intraperitoneal, Systemic
01
Overview
Band Therapeutics (also known as Guardian Therapeutics) is developing an anti-GPC3 aptamer for the treatment of various cancers. Glypican-3 (GPC3) is a cell-surface heparan sulfate proteoglycan that is significantly overexpressed in hepatocellular carcinoma and other solid tumors, while remaining largely absent in healthy adult tissues, making it a highly specific target for oncology. This therapeutic aptamer is designed to bind GPC3 on the surface of tumor cells. The program is currently in the early stages of development, specifically lead optimization or preclinical studies, as part of the company's broader portfolio of aptamer-based therapeutics.
- Other names
- Anti-GPC3Anti-GPC-3Anti-GPC 3GPC3-targeting aptamerGPC-3-targeting aptamerGPC 3-targeting aptamer
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on anti-GPC3 aptamer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-GPC3 aptamer.